Document Detail

MedLine Citation:
PMID:  20205487     Owner:  NLM     Status:  MEDLINE    
Pilsicainide is a class Ic antiarrhythmic agent used for the treatment of supraventricular and ventricular tachycardia. The pharmacodynamic effects of pilsicainide are achieved via selective sodium channel blockade. In randomized, multicentre trials in patients with atrial fibrillation, restoration of sinus rhythm was achieved in significantly more patients treated with a single oral dose of pilsicainide than those who received placebo, and in a numerically higher proportion of oral pilsicainide than intravenous disopyramide recipients. In another well designed trial in patients with persistent atrial fibrillation, the proportion of patients whose arrhythmia converted to normal sinus rhythm was significantly higher among those randomized to receive 2 weeks of oral pilsicainide therapy than among patients who received placebo. Over a 1-year period, both pilsicainide and cibenzoline (another class Ic agent) were effective in preventing recurrence of atrial fibrillation in a substantial proportion of patients in a single-centre crossover trial. There were no between-group differences in the subgroup of patients with shorter-duration atrial fibrillation, but actuarial results over 1 year significantly favoured cibenzoline over pilsicainide in patients with longer-duration atrial fibrillation. Both oral and intravenous pilsicainide have demonstrated efficacy in ventricular tachyarrhythmias, including ventricular extrasystole. Clinical trial and postmarketing surveillance data indicate that pilsicainide is generally well tolerated in most patients.
Greg L Plosker
Related Documents :
11225937 - Stroke prevention practices in patients with atrial fibrillation and pacemaker therapy:...
8205657 - Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embo...
1185887 - Persistent atrial standstill due to atrial inexcitability. an electrophysiological and ...
7407757 - Use of right atrial catheter for prolonged iv support in cancer patients.
7564487 - Effects of corticosteroid inhalation therapy on the deposition pattern of tc-99m human ...
3183007 - Antithrombin iii in the diagnosis of infection in febrile neutropenic patients.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  70     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-03-08     Completed Date:  2010-07-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  455-67     Citation Subset:  IM    
Adis, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Arrhythmia Agents / administration & dosage,  adverse effects,  pharmacology,  therapeutic use
Lidocaine / administration & dosage,  adverse effects,  analogs & derivatives*,  pharmacology,  therapeutic use
Tachycardia / drug therapy*
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 137-58-6/Lidocaine; 88069-49-2/pilsicainide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tolvaptan.
Next Document:  Fospropofol.